YY1000
2週前
I don't know about biggest, but certainly my costliest investing mistake...
Any reason not to sell today? I have not tendered any shares and this way I get the money a day early...
Updating the previous version of this message, on 1000 share trades Schwab gives me 3.6505, but on 50,000 shares I got 3.6500, so I don't see a way to get a better price, even though several trades go through at 3.655...
Emannow
2週前
Allergan continues to lose market share in both toxin and filler!
Sadly, Foley blew all the RVNC’s cash with his terrible decisions and destroyed the company! Now Bill Meury from Crown Labs told me years ago, that Foley was a terrible person and idiot! Bill was right!!!
Global net revenues from the aesthetics portfolio were $1.298 billion, a decrease of 5.2 percent on a reported basis, or 4.4 percent on an operational basis.
Global Botox Cosmetic net revenues were $687 million, a decrease of 4.2 percent on a reported basis, or 3.4 percent on an operational basis.
Global Juvederm net revenues were $279 million, a decrease of 16.3 percent on a reported basis, or 15.1 percent on an operational basis.
stocksrising
1月前
better than most of us who sold ALL ( some at $6.51 and $3.07ish).. only some friends and fam didn't sell/tender yet.. Crown not giving bod much time to decide, shotgun wedding it seems :)....will be interesting* if Teox comes back today with any filings( Sec, or RVNC) with higher bid, or at this point, who knows?????
actually don't care anymore with this drama show, just focusing on 3 other potential 5/10 baggers in 2025...
* for existing SH's
whoswho
1月前
Item 8. Additional Information to be Furnished.
Item 8 (“Additional Information”) of the Schedule 14D-9 is hereby amended and supplemented by adding the following information set forth below after the last paragraph of the subsection entitled “Subsequent Events”:
On January 16, 2025, Crown provided to Revance non-binding proposed amendments to the A&R Merger Agreement, Equity Commitment Letter and Limited Guarantee (together, the “Crown Proposal”). The Crown Proposal contemplates the following material changes to the terms of the A&R Merger Agreement: (i) an increase in the Offer Price to $3.65 per share; (ii) an increase in the Company Termination Fee to $15,290,488.66; and (iii) an increase in the Parent Termination Fee to $22,935,732.99. The Crown Proposal remains subject to formal consent and approval from both Crown’s Board of Directors and Revance’s Board. Crown indicated that the $3.65 offer expires at 4:10 p.m., Eastern Time, on January 17, 2025. The Revance Board will evaluate the Crown Proposal consistent with its duties.